☆ 4.7 Letter

Financial toxicity and cancer treatments: Help from biosimilars - The explanatory case of bevacizumab

EUROPEAN JOURNAL OF CANCER (2021)

Journal

EUROPEAN JOURNAL OF CANCER

Volume 143, Issue -, Pages 40-42

Publisher

ELSEVIER SCI LTD

DOI: 10.1016/j.ejca.2020.11.004

Keywords

Bevacizumab; Biosimilar; Phase III RCT; Cost of drugs

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.